SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues DeclineZacks Investment Research • 11/06/26
Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/06/26
Here's Why You Should Hold Solventum Stock in Your Portfolio for NowZacks Investment Research • 11/05/26
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 11/04/26
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?Zacks Investment Research • 11/02/26
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/29/26
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.TherapyZacks Investment Research • 10/23/26
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*PRNewsWire • 10/19/26
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical NamesZacks Investment Research • 10/05/26
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/04/26
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?Zacks Investment Research • 09/02/26